PHIA Koninklijke Philips N.V.

Philips and Paige team up to bring Artificial Intelligence (AI) to clinical pathology diagnostics

Philips and Paige team up to bring Artificial Intelligence (AI) to clinical pathology diagnostics

December 5, 2019

AI-based  cancer assessment tools are poised to help pathologists improve speed and accuracy of cancer diagnostics, ultimately leading to better patient care

Amsterdam, The Netherlands – ( (NYSE: PHG, AEX: PHIA), a global leader in health technology, and , a leader in computational pathology, announced today a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist’s workflow and treatment planning for patients.

Pathologists play a crucial role in the detection and diagnosis of a broad range of diseases, including cancer. The increasing number of cancer cases in the aging population, and rapid advances in personalized medicine have resulted in significant increases in the complexity of pathology diagnostics and the workload imposed on pathologists. Digital images of tissue samples make it possible for pathologists to easily diagnose these samples on a computer display using advanced imaging analysis and workflow software.

Paige’s technology has demonstrated , and the collaboration aims to deliver this kind of technology into routine clinical practice. Several pathology laboratories have already converted their glass slide-based workflow to digital, using the solution from Philips. Once digital images are available, the CE marked Paige Prostate software is applied automatically to detect and localize prostate cancer. This technology provides pathologists with valuable information they can use in their evaluation of prostate biopsies.

“We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer,” said Marlon Thompson, Business Leader of Digital & Computational Pathology at Philips. “Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”

“Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making,” said Leo Grady, CEO of Paige. “Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients.”

in combination with Paige Prostate aims to provide an intuitive digital & computational pathology workflow experience. Philips plans to offer the CE-marked Paige Prostate to European pathology labs in 2020. AI solutions for other markets and additional disease areas are expected to follow suit. Visit and  . for more information.

For further information, please contact:

Joost Maltha

Philips Global Press Office

Tel. : 6

Email:  

Nicole Rodrigues

NRPR Group – For Paige

Tel.:

Email:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About Paige.AI

Paige.AI is the leading start-up focused on building the best artificial intelligence in clinical medicine to transform how doctors diagnose and treat cancer. Based in New York, Paige.AI is bringing together the world’s leading experts in AI, computational pathology and clinical practice to improve patient care through a quantum leap forward in efficacy and efficiency. For more information, please visit: .

 

Attachment

EN
05/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch